Exact Sciences Corporation maintained revenue guidance for the full year of 2024. For the period, the company has maintained its revenue guidance of $2.810 billion to $2.850 billion, assuming: screening revenue of $2.155 billion to $2.175 billion, and precision oncology revenue of $655 billion to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.09 USD | -2.43% |
|
+3.91% | -40.40% |
Jun. 27 | Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target | MT |
Jun. 26 | BTIG Lowers Price Target on Exact Sciences to $70 From $80, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.40% | 8.34B | |
+2.22% | 3.37B | |
-7.26% | 2.04B | |
-28.23% | 1.77B | |
-22.68% | 1.66B | |
+15.57% | 976M | |
+21.83% | 814M | |
-9.61% | 707M | |
-27.76% | 532M | |
-16.10% | 241M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024